Free Trial

Regeneron Pharmaceuticals (REGN) SEC Filings & 10K Form

Regeneron Pharmaceuticals logo
$558.87 +13.41 (+2.46%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$564.00 +5.13 (+0.92%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Regeneron Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/01/2025
5:56 AM
Regeneron Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2025
5:49 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2025
10:11 AM
JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Regeneron Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/02/2025
3:15 PM
Regeneron Pharmaceuticals (Filer)
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
04/29/2025
5:51 AM
Regeneron Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2025
5:37 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2025
5:03 AM
Regeneron Pharmaceuticals (Filer)
Form DEF 14A
04/29/2025
5:04 AM
Regeneron Pharmaceuticals (Filer)
Form DEFA14A
04/29/2025
5:12 AM
Regeneron Pharmaceuticals (Filer)
Form ARS
04/22/2025
11:01 AM
JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Regeneron Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
04/07/2025
3:15 PM
Regeneron Pharmaceuticals (Filer)
Form PRE 14A
02/12/2025
8:30 AM
FMR LLC (Filed by)
Regeneron Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/07/2025
3:36 PM
Regeneron Pharmaceuticals (Filer)
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
02/05/2025
8:18 AM
Regeneron Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/04/2025
6:11 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
5:37 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2025
4:42 PM
Regeneron Pharmaceuticals (Issuer)
Schenkein David P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:01 PM
Fenimore Christopher R. (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:01 PM
LAROSA JOSEPH J (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:02 PM
McCourt Marion (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:02 PM
MURPHY ANDREW J (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:02 PM
Pitofsky Jason (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:02 PM
Regeneron Pharmaceuticals (Issuer)
STAHL NEIL (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:03 PM
Regeneron Pharmaceuticals (Issuer)
Van Plew Daniel P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/01/2024
3:38 PM
McCourt Marion (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/31/2024
3:33 PM
Regeneron Pharmaceuticals (Filer)
Form S-3ASR
10/31/2024
6:16 AM
Regeneron Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/31/2024
6:10 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/07/2024
6:00 AM
Regeneron Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2024
3:01 PM
Regeneron Pharmaceuticals (Issuer)
RYAN ARTHUR F (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
3:01 PM
McCourt Marion (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
3:01 PM
Regeneron Pharmaceuticals (Issuer)
SING GEORGE L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2024
3:27 PM
Fenimore Christopher R. (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2024
3:35 PM
Fenimore Christopher R. (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2024
4:55 PM
POON CHRISTINE A (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2024
10:45 AM
Bassler Bonnie L (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/08/2024
3:53 PM
Regeneron Pharmaceuticals (Subject)
STAHL NEIL (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:33 PM
Pitofsky Jason (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:40 PM
Pitofsky Jason (Reporting)
Regeneron Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/02/2024
9:43 AM
Bassler Bonnie L (Reporting)
Regeneron Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:REGN) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners